Clinical Trials on Major Depressive Disorder - MDD in Hungary

Total 48 results

Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Janssen Research & Development, LLC

Completed

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Major Depressive Disorder

Ukraine, Bulgaria, Romania, Russian Federation, Hungary, Moldova, Republic of
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Hungary, India
AstraZeneca

Completed

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients (RUBY)

Major Depressive Disorder | Treatment Resistant Depression

Bulgaria, Italy, United Kingdom, Germany, Hungary, Romania, Austria, Belgium, Denmark, Portugal, Slovakia, Australia, Spain
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
AbbVie

Completed

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Bulgaria, Estonia, Germany, Hungary, Ukraine, United Kingdom
Intra-Cellular Therapies, Inc.

Enrolling by invitation

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Germany, Hungary, Poland, Finland, India, Korea, Republic of, Sweden
Eli Lilly and Company

Completed

Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder

Major Depressive Disorder

Denmark, France, Greece, Hungary, Italy, Netherlands, Romania, Slovenia, Spain, Sweden, Turkey
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

Sweden, Czech Republic, Poland, Germany, Estonia, Latvia, Lithuania, Finland, France, Hungary
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
Alkermes, Inc.

Completed

A Long-Term Safety Study of ALKS 5461

Major Depressive Disorder

United States, Canada, Germany, Puerto Rico, Bulgaria, Australia, Poland, Hungary
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Slovakia, Poland, Hungary, Japan, Russian Federation
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Major Depressive Disorder

Croatia, Brazil, Bulgaria, France, Poland, Russian Federation, South Africa, Hungary, Romania, Ukraine, Argentina, Chile, Slovakia, Colombia, Germany, Serbia, Spain
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
Janssen-Cilag Ltd.

Active, not recruiting

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (ESCAPE-LTE)

Depressive Disorder, Major

Taiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Poland, Hungary, Japan, Slovakia
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Bulgaria, Canada, Colombia, Estonia, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Poland, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
H. Lundbeck A/S
Takeda

Completed

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, United States, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Mexico, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Latvia, South Africa
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

Depressive Disorder, Major

United States, Korea, Republic of, Taiwan, Slovakia, Spain, Bulgaria, Poland, Belgium, Argentina, Czechia, Hungary, South Africa, Sweden, Italy, France, Australia, China, Brazil, Portugal
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Janssen Research & Development, LLC

Completed

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire I)

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Taiwan, Bulgaria, Spain, Hungary, Germany, Estonia, South Africa, Slovakia
Sunovion

Completed

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

Insomnia | Major Depressive Disorder

France, Poland, Russian Federation, United Kingdom, Austria, Hungary, Croatia, Romania, Serbia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Janssen Research & Development, LLC

Completed

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Depressive Disorder, Major

United States, France, Italy, Spain, Hungary, Belgium, Brazil, Bulgaria, Poland
Semmelweis University

Completed

Adherence to the iFightDepression Online Self-help Tool for Mild and Moderate Depression

Depression

Hungary
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Treatment-resistant Depression

United States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
Cephalon

Completed

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Bipolar I Depression

United States, Bulgaria, Hungary, Romania
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Sunovion

Completed

Lurasidone Pediatric Bipolar Study (Illuminate)

Bipolar I Depression

United States, Korea, Republic of, Bulgaria, Poland, Mexico, Puerto Rico, Colombia, Hungary, France, Philippines, Ukraine
Pfizer

Completed

Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression

Depression | Smoking Cessation

Spain, United States, Hungary, Germany, Bosnia and Herzegovina, Croatia, Romania, Russian Federation
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

United States, Argentina, Brazil, Bulgaria, Croatia, Finland, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Ukraine
Cephalon

Terminated

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, South Africa, Spain, Ukraine
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia
Sanofi

Completed

STILDEP: Zolpidem in Depressive and Dysthimic Patients

Depression | Sleep Initiation and Maintenance Disorders

Hungary
Szeged University

Completed

Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population

Coping Skills | Mood | COVID-19 Pandemic | Psychological Stress | Subjective Health Complaint | Questionnaire Designs | Two-Item Generalised Anxiety Disorder Scale | Patient Health Questionnaire Anxiety and Depression Scale | Health Status Index

Hungary
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Alzheimer's Disease

Brazil, South Africa, Chile, Hungary, Bulgaria, Czechia, Germany, Japan, Mexico, Poland, Russian Federation, Slovakia
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine
Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
Forest Laboratories

Completed

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine, Australia, Canada, France, Singapore
Sunovion

Completed

Pediatric Open-Label Extension Study

Schizophrenia | Bipolar Depression | Autism

Korea, Republic of, United States, Malaysia, Bulgaria, Poland, Mexico, Colombia, France, Hungary, Philippines, Puerto Rico, Romania, Russian Federation, Spain, Ukraine
Santhera Pharmaceuticals

Terminated

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids (SIDEROS)

Duchenne Muscular Dystrophy (DMD)

United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more

Clinical Trials on Major Depressive Disorder - MDD in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations